TABLE 2.
Site | Reference standard (n/N) | TP | TN | FN | FP | Sensitivity CI (%) | Specificity CI (%) | PPV CI (%) | NPV CI (%) | F-score CI |
---|---|---|---|---|---|---|---|---|---|---|
KPSC | 14/421 | 12 | 401 | 2 | 6 | 85.7 57.2–98.2 |
98.5 96.8–99.5 |
66.7 41.0–86.7 |
99.5 98.2–99.9 |
0.83 0.98–1.00 |
Site 2 | 1/46 | 0 | 42 | 1 | 3 | 0.0 | 93.3 81.7–98.6 |
0.0 | 97.7 87.7–99.9 |
0.00 |
Site 3 | 0/104 | 0 | 102 | 0 | 2 | NA | 98.1 93.2–99.8 |
0.0 | 100.0 97.1–100 |
NA |
Site 4 | 1/75 | 0 | 72 | 1 | 2 | 0.0 | 97.3 90.6–99.7 |
0.0 | 98.6 92.6–99.9 |
0.00 |
Site 5 | 1/67 | 0 | 62 | 1 | 4 | 0.0 | 93.9 85.2–98.3 |
0.0 | 98.4 91.5–99.9 |
0.00 |
Note: 95% confidence intervals are displayed beneath point estimates. Reference standard: 2009 to 2011 anaphylaxis cases abstracted and adjudicated as part of McNeil et al study.
Abbreviations: F-score: , with β = 3; FN, false negative—NLP negative, reference standard positive; FP, false positive—NLP positive, reference standard negative; n, number of positive vaccine-related anaphylaxis cases; N, number of cases reviewed; NPV, negative predictive value; TN, true negative—NLP negative, reference standard negative; TP, true positive—NLP positive, reference standard positive; PPV, positive predictive value.